BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani M. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer 2017;117:1269-77. [PMID: 29065426 DOI: 10.1038/bjc.2017.289] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Delhorme J, Bersuder E, Terciolo C, Vlami O, Chenard M, Martin E, Rohr S, Brigand C, Duluc I, Freund J, Gross I. CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancer. Biomedicine & Pharmacotherapy 2022;147:112630. [DOI: 10.1016/j.biopha.2022.112630] [Reference Citation Analysis]
2 Imyanitov EN, Iyevleva AG. Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. Cancer Lett 2022;526:41-52. [PMID: 34808283 DOI: 10.1016/j.canlet.2021.11.021] [Reference Citation Analysis]
3 Gmeiner WH. A narrative review of genetic factors affecting fluoropyrimidine toxicity. Precis Cancer Med 2021;4:38. [PMID: 34901834 DOI: 10.21037/pcm-21-17] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Božina N, Bilić I, Ganoci L, Šimičević L, Pleština S, Lešnjaković L, Trkulja V. DPYD polymorphisms c.496A>G, c.2194G>A and c.85T>C and risk of severe adverse drug reactions in patients treated with fluoropyrimidine-based protocols. Br J Clin Pharmacol 2021. [PMID: 34780066 DOI: 10.1111/bcp.15144] [Reference Citation Analysis]
5 Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD Variants and Treatment-Related Mortality in Patients Receiving Fluoropyrimidine Chemotherapy: A Systematic Review and Meta-Analysis. Oncologist 2021. [PMID: 34506675 DOI: 10.1002/onco.13967] [Reference Citation Analysis]
6 Villalvazo P, Marzal-Alfaro B, García-Alfonso P, Revuelta-Herrero JL, Thomas F, López-Tarruella S, García-González X, Calvo A, Yakoubi M, Salvador-Martín S, López-López F, Aguilar I, Sanjurjo-Sáez M, Martín M, López-Fernández LA. DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach. J Pers Med 2021;11:792. [PMID: 34442436 DOI: 10.3390/jpm11080792] [Reference Citation Analysis]
7 Hamzic S, Schärer D, Offer SM, Meulendijks D, Nakas C, Diasio RB, Fontana S, Wehrli M, Schürch S, Amstutz U, Largiadèr CR. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity. Br J Clin Pharmacol 2021;87:3234-43. [PMID: 33491253 DOI: 10.1111/bcp.14742] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Vivaldi C, Crucitta S, Catanese S, Cucchiara F, Arrigoni E, Pecora I, Rofi E, Fornaro L, Salani F, Massa V, Vasile E, Morganti R, Danesi R, Del Re M. Comprehensive pharmacogenetic analysis of DPYD, UGT, CDA, and ABCB1 polymorphisms in pancreatic cancer patients receiving mFOLFIRINOX or gemcitabine plus nab-paclitaxel. Pharmacogenomics J 2021;21:233-42. [PMID: 33462346 DOI: 10.1038/s41397-020-00203-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Ba Y, Shi Y, Jiang W, Feng J, Cheng Y, Xiao L, Zhang Q, Qiu W, Xu B, Xu R, Shen B, Luo Z, Xie X, Chang J, Wang M, Li Y, Shuang Y, Niu Z, Liu B, Zhang J, Zhang L, Yao H, Xie C, Huang H, Liao W, Chen G, Zhang X, An H, Deng Y, Gong P, Xiong J, Yao Q, An X, Chen C, Shi Y, Wang J, Wang X, Wang Z, Xing P, Yang S, Zhou C. Current management of chemotherapy-induced neutropenia in adults: key points and new challenges: Committee of Neoplastic Supportive-Care (CONS), China Anti-Cancer Association Committee of Clinical Chemotherapy, China Anti-Cancer Association. Cancer Biol Med 2020;17:896-909. [PMID: 33299642 DOI: 10.20892/j.issn.2095-3941.2020.0069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Naushad SM, Hussain T, Alrokayan SA, Kutala VK. Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population. J Gene Med 2021;23:e3289. [PMID: 33105068 DOI: 10.1002/jgm.3289] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
11 Simões AR, Fernández-Rozadilla C, Maroñas O, Carracedo Á. The Road so Far in Colorectal Cancer Pharmacogenomics: Are We Closer to Individualised Treatment? J Pers Med 2020;10:E237. [PMID: 33228198 DOI: 10.3390/jpm10040237] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Bruera G, Ricevuto E; Oncology Network ASL1 Abruzzo. Pharmacogenomic Assessment of Patients with Colorectal Cancer and Potential Treatments. Pharmgenomics Pers Med 2020;13:601-17. [PMID: 33235483 DOI: 10.2147/PGPM.S253586] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Puerta-García E, Urbano-Pérez D, Carrasco-Campos MI, Pérez-Ramírez C, Segura-Pérez A, Calleja-Hernández, Cañadas-Garre M. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma. Surg Oncol 2020;35:388-98. [PMID: 33035787 DOI: 10.1016/j.suronc.2020.09.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Deac AL, Burz CC, Bocşe HF, Bocşan IC, Buzoianu AD. A review on the importance of genotyping and phenotyping in fluoropyrimidine treatment. Med Pharm Rep 2020;93:223-30. [PMID: 32832886 DOI: 10.15386/mpr-1564] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 De Mattia E, Roncato R, Palazzari E, Toffoli G, Cecchin E. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy. Front Pharmacol 2020;11:897. [PMID: 32625092 DOI: 10.3389/fphar.2020.00897] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Rong H, Dong H, He X, Yuan D, Bai M, Wang L, Liu T, He Y, Zheng J, Wang Y, Jin T. Analysis of very important pharmacogene variants in the Tibetan population from China. Clin Exp Pharmacol Physiol 2021;48:668-78. [PMID: 32311112 DOI: 10.1111/1440-1681.13327] [Reference Citation Analysis]
17 Bolzacchini E, Luchena G, Giordano M. Safety Report of TAS-102 in a Patient With Reduced DPD Activity. Clinical Colorectal Cancer 2019;18:310-2. [DOI: 10.1016/j.clcc.2019.07.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Espregueira Themudo G, Leerschool AR, Rodriguez-Proano C, Christiansen SL, Andersen JD, Busch JR, Christensen MR, Banner J, Morling N. Targeted exon sequencing in deceased schizophrenia patients in Denmark. Int J Legal Med 2020;134:135-47. [PMID: 31773318 DOI: 10.1007/s00414-019-02212-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Miscio G, Paroni G, Bisceglia P, Gravina C, Urbano M, Lozupone M, Piccininni C, Prisciandaro M, Ciavarella G, Daniele A, Bellomo A, Panza F, Di Mauro L, Greco A, Seripa D. Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline. Expert Opin Drug Metab Toxicol 2019;15:751-65. [PMID: 31512953 DOI: 10.1080/17425255.2019.1658742] [Reference Citation Analysis]
20 Sharma V, Gupta SK, Verma M. Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs. Cancer Chemother Pharmacol 2019;84:1157-66. [DOI: 10.1007/s00280-019-03936-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
21 Lee LYW, Starkey T, Sivakumar S, Fotheringham S, Mozolowski G, Shearwood V, Palles C, Camilleri P, Church D, Kerr R, Kerr D. ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single-center clinical utility study-PRECISE study. Cancer Med 2019;8:6305-14. [PMID: 31486228 DOI: 10.1002/cam4.2529] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
22 Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Magnani M. Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy. Sci Rep 2019;9:11527. [PMID: 31395900 DOI: 10.1038/s41598-019-47627-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
23 Palmirotta R, Lovero D, Delacour H, Le Roy A, Cremades S, Silvestris F. Rare Dihydropyrimidine Dehydrogenase Variants and Toxicity by Floropyrimidines: A Case Report. Front Oncol 2019;9:139. [PMID: 30915274 DOI: 10.3389/fonc.2019.00139] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Iachetta F, Bonelli C, Romagnani A, Zamponi R, Tofani L, Farnetti E, Nicoli D, Damato A, Banzi M, Casali B, Pinto C. The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study. Br J Cancer 2019;120:834-9. [PMID: 30858516 DOI: 10.1038/s41416-019-0423-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
25 Inoue F, Yano T, Nakahara M, Okuda H, Amano H, Yonehara S, Noriyuki T. Cytomegalovirus enterocolitis in a patient with dihydropyrimidine dehydrogenase deficiency after capecitabine treatment: A case report. Int J Surg Case Rep 2019;56:55-8. [PMID: 30831507 DOI: 10.1016/j.ijscr.2019.02.022] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Stavraka C, Pouptsis A, Okonta L, DeSouza K, Charlton P, Kapiris M, Marinaki A, Karapanagiotou E, Papadatos-Pastos D, Mansi J. Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients. Breast Cancer Res Treat 2019;175:511-7. [PMID: 30746637 DOI: 10.1007/s10549-019-05144-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
27 Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R. DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics J. 2019;19:556-563. [PMID: 30723313 DOI: 10.1038/s41397-019-0077-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
28 Hlavac V, Kovacova M, Elsnerova K, Brynychova V, Kozevnikovova R, Raus K, Kopeckova K, Mestakova S, Vrana D, Gatek J, Ostasov P, Vaclavikova R, Soucek P. Use of Germline Genetic Variability for Prediction of Chemoresistance and Prognosis of Breast Cancer Patients. Cancers (Basel) 2018;10:E511. [PMID: 30545124 DOI: 10.3390/cancers10120511] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
29 Velez-Velez LM, Hughes CL, Kasi PM. Clinical Value of Pharmacogenomic Testing in a Patient Receiving FOLFIRINOX for Pancreatic Adenocarcinoma. Front Pharmacol 2018;9:1309. [PMID: 30498448 DOI: 10.3389/fphar.2018.01309] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
30 Tong CC, Lam CW, Lam KO, Lee VHF, Luk MY. A Novel DPYD Variant Associated With Severe Toxicity of Fluoropyrimidines: Role of Pre-emptive DPYD Genotype Screening. Front Oncol 2018;8:279. [PMID: 30087856 DOI: 10.3389/fonc.2018.00279] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
31 Battaglin F, Puccini A, Naseem M, Schirripa M, Berger MD, Tokunaga R, McSkane M, Khoukaz T, Soni S, Zhang W, Lenz HJ. Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives. J Cancer Metastasis Treat 2018;4:12. [PMID: 34532592 DOI: 10.20517/2394-4722.2018.04] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]